Combining immunotherapy with chemotherapy shows promise in enhancing survival rates for extensive-stage small cell lung ...

It had been hoped that RA patients might actually benefit more from these drugs, known as immune checkpoint inhibitors (ICIs) ...

chemotherapy in HR+, HER2-low metastatic breast cancer ... in a pCR rate of 17.2% versus 4.3% for patients treated with neoadjuvant chemotherapy alone. Additionally, interim overall survival ...

Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in ...

A real-world study from India demonstrated that ultralow-dose nivolumab (40 mg every 2 weeks) combined with chemotherapy showed promising results in non–small cell lung cancer (NSCLC).

First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy "Small cell lung cancer is one of the ...

Boehringer Ingelheim’s drug candidate for human epidermal growth factor receptor 2 (HER2)-mutated non-small cell lung cancer ...

While there have been massive strides forward in treating cancer in the last decades – with a doubling in survival rates in the last ... and an ongoing lung cancer screening drive rolled out ...